See more : Asian Hotels (West) Limited (AHLWEST.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Extrawell Pharmaceutical Holdings Limited (0858.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Extrawell Pharmaceutical Holdings Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Watahan & Co.,Ltd. (3199.T) Income Statement Analysis – Financial Results
- Rockhaven Resources Ltd. (RK.V) Income Statement Analysis – Financial Results
- Akanda Corp. (AKAN) Income Statement Analysis – Financial Results
- Melcor Real Estate Investment Trust (MR-UN.TO) Income Statement Analysis – Financial Results
- First Foods Group, Inc. (FIFG) Income Statement Analysis – Financial Results
Extrawell Pharmaceutical Holdings Limited (0858.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.extrawell.com.hk
About Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and Gene Development segments. It offers transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. In addition, it is involved in the marketing and distribution of imported pharmaceutical products, including Millibar for the treatment of high blood pressure; and development of oral insulin. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.10M | 72.58M | 73.93M | 78.80M | 77.58M | 89.22M | 85.76M | 107.90M | 142.20M | 128.83M | 150.67M | 151.07M | 157.41M | 198.82M | 196.29M | 184.43M | 165.08M | 158.76M | 178.27M | 169.77M | 215.63M | 215.52M | 199.50M | 135.16M | 126.98M |
| Cost of Revenue | 30.32M | 41.43M | 36.37M | 36.24M | 34.67M | 39.62M | 43.71M | 64.01M | 72.89M | 77.78M | 110.51M | 104.37M | 109.94M | 146.79M | 142.45M | 126.55M | 113.00M | 110.00M | 108.45M | 123.68M | 135.08M | 118.31M | 113.74M | 73.74M | 85.10M |
| Gross Profit | 28.78M | 31.14M | 37.56M | 42.57M | 42.92M | 49.60M | 42.05M | 43.90M | 69.31M | 51.06M | 40.16M | 46.69M | 47.46M | 52.03M | 53.84M | 57.89M | 52.08M | 48.77M | 69.82M | 46.09M | 80.56M | 97.21M | 85.76M | 61.42M | 41.88M |
| Gross Profit Ratio | 48.70% | 42.91% | 50.80% | 54.02% | 55.32% | 55.59% | 49.03% | 40.68% | 48.74% | 39.63% | 26.65% | 30.91% | 30.15% | 26.17% | 27.43% | 31.39% | 31.55% | 30.72% | 39.16% | 27.15% | 37.36% | 45.10% | 42.99% | 45.44% | 32.98% |
| Research & Development | 194.00K | 881.00K | 444.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.61M | 4.08M | 3.25M | 4.89M | 8.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 22.16M | 25.74M | 24.21M | 23.89M | 26.45M | 26.40M | 27.01M | 27.23M | 26.47M | 29.32M | 34.15M | 27.89M | 27.23M | 29.42M | 28.42M | 30.60M | 35.30M | 26.66M | 36.08M | 29.44M | 32.77M | 28.47M | 24.70M | 23.45M | 14.01M |
| Selling & Marketing | 13.18M | 16.68M | 26.29M | 29.54M | 24.55M | 40.17M | 32.26M | 31.67M | 42.36M | 36.21M | 15.42M | 9.52M | 10.43M | 16.48M | 20.65M | 23.19M | 16.32M | 14.44M | 14.89M | 17.05M | 18.82M | 17.78M | 13.59M | 10.02M | 12.90M |
| SG&A | 35.33M | 41.42M | 55.57M | 49.55M | 59.25M | 66.57M | 59.27M | 58.90M | 68.83M | 65.52M | 49.57M | 37.40M | 37.66M | 45.90M | 49.07M | 53.78M | 51.62M | 41.09M | 50.97M | 46.48M | 51.58M | 46.25M | 38.29M | 33.47M | 26.92M |
| Other Expenses | 0.00 | 437.00K | 209.00K | 0.00 | 2.00K | 0.00 | 0.00 | 2.87M | 228.00K | 222.00K | 224.00K | 222.00K | -3.56M | -11.59M | -13.52M | -6.68M | -2.10M | 8.69M | 15.89M | 86.41M | 85.37M | 14.91M | 1.48M | 4.32M | 987.00K |
| Operating Expenses | 35.53M | 42.30M | 56.01M | 49.55M | 59.25M | 11.64M | 96.62M | 96.54M | 103.78M | 79.64M | 51.66M | 36.66M | 38.98M | 42.65M | 35.55M | 47.11M | 49.52M | 49.78M | 66.86M | 132.89M | 136.96M | 61.16M | 39.77M | 37.80M | 27.91M |
| Cost & Expenses | 65.85M | 83.73M | 92.38M | 85.79M | 93.92M | 51.26M | 140.33M | 160.55M | 176.66M | 157.42M | 162.17M | 141.03M | 148.93M | 189.43M | 178.00M | 173.66M | 162.52M | 159.78M | 175.31M | 256.57M | 272.03M | 179.48M | 153.52M | 111.54M | 113.01M |
| Interest Income | 5.67M | 2.99M | 1.08M | 5.17M | 12.81M | 2.13M | 83.75M | 71.57M | 61.95M | 39.90M | 2.11M | 1.72M | 1.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 18.80M | 15.64M | 13.23M | 11.24M | 9.35M | 7.82M | 6.59M | 5.55M | 4.69M | 3.94M | 6.89M | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.91M | 8.67M | 8.63M | 8.06M | 6.30M | 6.24M | 6.33M | 6.43M | 6.29M | 6.03M | 2.88M | 3.09M | 4.07M | 3.84M | 5.72M | 6.16M | 5.24M | 5.29M | 5.82M | 17.24M | 24.58M | 17.07M | -5.61M | -3.59M | -3.74M |
| EBITDA | -129.52M | 159.05M | 157.84M | -97.48M | 101.14M | 77.43M | 42.45M | 31.29M | 6.78M | -42.18M | 42.71M | 12.98M | 20.93M | 8.94M | 18.51M | 14.15M | 7.79M | 4.28M | 13.43M | -79.42M | -31.82M | 53.12M | 51.53M | 23.62M | 13.97M |
| EBITDA Ratio | -219.16% | -3.43% | -13.29% | 1.37% | -12.93% | -11.97% | -12.63% | -7.90% | 4.77% | 12.45% | -4.17% | 8.69% | 7.97% | 8.80% | 12.23% | 10.69% | 4.72% | 2.69% | 4.92% | -40.97% | -14.76% | 24.65% | 23.05% | 17.47% | 11.00% |
| Operating Income | -8.16M | -11.15M | -18.46M | -6.99M | -16.33M | -16.97M | -17.22M | -15.01M | 486.00K | -48.21M | 37.79M | 11.97M | 8.48M | 5.10M | 12.79M | 7.99M | 2.56M | 9.50M | 7.61M | -85.63M | -31.73M | 57.36M | 51.59M | 27.21M | 17.71M |
| Operating Income Ratio | -13.81% | -15.37% | -24.97% | -8.86% | -21.05% | -19.02% | -20.08% | -13.91% | 0.34% | -37.42% | 25.08% | 7.92% | 5.39% | 2.57% | 6.51% | 4.33% | 1.55% | 5.98% | 4.27% | -50.44% | -14.72% | 26.61% | 25.86% | 20.13% | 13.94% |
| Total Other Income/Expenses | -151.35M | 145.90M | 148.43M | -108.05M | 97.97M | 80.35M | 46.23M | 33.94M | 27.00M | -39.27M | 40.31M | -1.37M | 8.38M | 0.00 | 0.00 | 5.65M | -164.00K | -197.00K | -908.00K | -2.20M | -4.10M | -3.71M | -2.53M | -1.77M | -1.59M |
| Income Before Tax | -159.51M | 134.75M | 135.98M | -116.78M | 85.49M | 63.37M | 29.19M | 18.93M | 27.49M | -52.15M | 30.90M | 8.89M | 16.86M | 5.10M | 12.79M | 7.99M | 2.39M | 9.30M | 6.70M | -87.84M | -35.84M | 53.64M | 49.06M | 25.44M | 16.11M |
| Income Before Tax Ratio | -269.91% | 185.66% | 183.95% | -148.20% | 110.19% | 71.03% | 34.03% | 17.54% | 19.33% | -40.48% | 20.51% | 5.88% | 10.71% | 2.57% | 6.51% | 4.33% | 1.45% | 5.86% | 3.76% | -51.74% | -16.62% | 24.89% | 24.59% | 18.82% | 12.69% |
| Income Tax Expense | 2.13M | 1.13M | 1.24M | 4.31M | -90.00K | 50.00K | 86.00K | 616.00K | 90.00K | 92.00K | 14.54M | 706.00K | 926.00K | 1.06M | -2.78M | -9.42M | 15.73M | 369.00K | 2.51M | -1.79M | 1.10M | 914.00K | 3.88M | 3.31M | 1.99M |
| Net Income | -162.95M | 129.27M | 130.59M | -121.10M | 83.28M | 64.03M | 29.93M | 20.80M | 27.40M | 565.46M | 15.70M | 10.88M | 20.41M | 11.57M | 14.62M | 15.55M | -13.34M | 8.93M | 4.19M | -75.82M | 14.64M | 46.69M | 42.00M | 20.54M | 14.04M |
| Net Income Ratio | -275.73% | 178.11% | 176.65% | -153.67% | 107.34% | 71.77% | 34.90% | 19.27% | 19.27% | 438.91% | 10.42% | 7.20% | 12.97% | 5.82% | 7.45% | 8.43% | -8.08% | 5.63% | 2.35% | -44.66% | 6.79% | 21.66% | 21.05% | 15.20% | 11.06% |
| EPS | -0.07 | 0.05 | 0.05 | -0.05 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.24 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | -0.01 | 0.00 | 0.00 | -0.03 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 |
| EPS Diluted | -0.07 | 0.04 | 0.04 | -0.05 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.24 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | -0.01 | 0.00 | 0.00 | -0.03 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 |
| Weighted Avg Shares Out | 2.39B | 2.39B | 2.39B | 2.39B | 2.39B | 3.29B | 3.29B | 3.29B | 3.29B | 2.39B | 3.01B | 2.29B | 2.29B | 2.29B | 2.29B | 2.29B | 2.29B | 2.28B | 2.33B | 2.30B | 2.29B | 2.27B | 1.95B | 1.90B | 1.90B |
| Weighted Avg Shares Out (Dil) | 2.39B | 3.29B | 3.29B | 2.39B | 3.29B | 3.29B | 3.29B | 3.29B | 3.29B | 2.39B | 3.01B | 2.29B | 2.29B | 2.29B | 2.29B | 2.29B | 2.29B | 2.28B | 2.33B | 2.30B | 2.29B | 2.27B | 1.95B | 1.90B | 1.90B |
Source: https://incomestatements.info
Category: Stock Reports